ClinicalTrials.gg
Not yet recruitingNCT07858123TRIADESUpdated Oct 5, 2026

Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

A Phase 3 interventional study of CHF5993 100/6/12.5 μg pMDI HFA-152a and Seretide Evohaler in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Not yet recruiting at 25 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
10th of 66
700 · median 97
Started
2026
with 3 others
Phase 3
24 of 81
2 open now
Primary completion
2030-06
later than 10 of 10 live
Registered
80th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 10th largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 80th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The CLI-05993AA5-06 study is an interventional study designed to investigate the safety and efficacy of a new experimental drug called CHF5993 pMDI compared to the currently approved Seretide 125 Evohaler pMDI in adolescent patients with uncontrolled asthma.

Read the detailed description

Outpatients attending the hospital clinics/study centers will be recruited. Uncontrolled asthma adolescent subjects will be recruited. A total of 420 subjects will be randomized. The whole study will last approximately 52 weeks for each subject.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's written obtained prior to any study related procedure;
  • Male and female adolescent aged ≥ 12 and \<18 years;
  • Subject participating in the Pharmacokinetic(s) (PK) part of the study, body weight should be ≥ 30kg
  • A documented history of asthma for at least 6 months
  • Subjects in treatment with double therapy with medium doses of inhaled (ICS) in fixed or free combination with a long-acting β2-agonist (LABA) ( > 500-1000 μg daily dose Beclomethasone Dipropionate non-extrafine or estimated clinically comparable dose plus formoterol 24 µg/day or salmeterol 100 µg/day or vilanterol 25 µg/day) at a stable dose for at least 4 weeks prior to screening;
  • Subjects must have a cooperative attitude and the ability to be trained to use correctly the pMDI inhalers and e-Diary, to be able to read/write, to be able to perform the required outcomes measurements (e.g., technically acceptable spirometry, e-Diary completion) and the ability to understand the risks involved.
  • Subjects with a pre-Bronchodilator (BD) (FEV1) ≤90% and ≥60% of their predicted normal value, after appropriate from BDs, at the Screening and Randomization Visits
  • Subjects with a positive response to a reversibility test at screening, defined as FEV1 ≥12% and ≥200 mL over baseline, 10 to 15 minutes (min) after inhaling 200-400 µg of salbutamol pMDI.
  • Subjects with uncontrolled asthma evidenced by an ACQ-7 total score ≥1.5 at screening;
  • A documented history of one or more asthma exacerbations requiring treatment with systemic corticosteroids (SCS) or emergency department visit or in-patient hospitalization in the previous 12 months;

Exclusion criteria

Exclusion Criteria:

  • History of "at risk" asthma: history of near fatal asthma or of a past hospitalization for asthma in an intensive care unit which, in the judgement of the Investigator, may place the subject at undue risk;
  • Recent exacerbation or respiratory tract infection: hospitalization, emergency room admission or use of SCS for an asthma exacerbation or a documented diagnosis of lower respiratory tract infection that required antibiotics or an unresolved respiratory tract infection within 4 weeks prior to Screening Visit (V1) or during the run-in period;
  • Respiratory disorders other than asthma: this can include but is not limited to: α1-antitrypsin deficiency, active tuberculosis, bronchiectasis, cystic fibrosis, sarcoidosis, pulmonary hypertension and interstitial lung disease;
  • Current smokers (including e-cigarettes, vaping and hookah), or ex-smokers with a smoking history of ≥5 pack-years (pack-years = the number of cigarette packs per day times the number of years), or current use of inhaled or oral cannabis products. Ex-smokers must have stopped smoking ≥1 year (≥6 months for e-cigarettes);
  • Other severe acute or chronic medical (such as but not limited to thyrotoxicosis, diabetes mellitus, and untreated hypokalemia) or or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study;
  • Any change in dose, schedule or formulation of the combination ICS plus LABA in the 4 weeks prior to Screening Visit (V1)
  • Subjects using SCS medication in the 4 weeks or slow-release in the 12 weeks, prior to screening
  • Only for subjects included in the subset for PK assessment:

Veins unsuitable for repeated venipuncture; Blood donation or blood loss (>450 mL) in the 4 weeks before randomization.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Inhaler CHF5993 100/6/12,5μg pMDI

    Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a

  • Active comparator
    Seretide Evohaler FP/SLM pMDI 125/25μg

    Drug: Seretide Evohaler

Interventions

  • DrugCHF5993 100/6/12.5 μg pMDI HFA-152a

    Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Beclomethasone Dipropionate (BDP)//Formoterol Fumarate (FF) /Glycopyrronium Bromide (GB) 100/6/12,5μg per actuation; Excipients: HFA-152a propellant.

  • DrugSeretide Evohaler

    Drug: Seretide Evohaler administered via Pressurized Metered Dose Inhaler (pMDI). Active ingredients: Fluticasone Propionate (FP)/Salmeterol Xinafoate (SLM) pMDI 125/25μg per actuation; Excipients: HFA-134a propellant.

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-dose Forced Expiratory Volume FEV1 in the first second (FEV1).

    Population summary measure is the adjusted mean between treatment difference comparing CHF5993 BDP/FF/GB pMDI vs. Seretide® Evohaler® FP/SLM pMDI in a Intent To Treat (ITT) Population to demonstrate the superiority of CHF5993 BDP/FF/GB pMDI compared to Seretide Evohaler FP/SLM pMDI

    Time frame: Baseline (pre-dose on Week 0) and Week 26

Secondary outcomes

  1. Change from baseline in 2h post-dose FEV1

    Population summary measure is the adjusted mean between treatment difference comparing CHF5993 BDP/FF/GB pMDI vs. Seretide® Evohaler® FP/SLM pMDI in ITT population to demonstrate the superiority of CHF5993 BDP/FF/GB pMDI compared to Seretide Evohaler FP/SLM pMDI

    Time frame: Baseline (pre-dose on Week 0) and Week 26

  2. Evaluation of Severe asthma exacerbations rate over the 52 weeks of treatment

    Time frame: Over the 52 weeks of treatment

  3. Time to first severe exacerbation during the entire 52 weeks of treatment

    Time frame: Over the 52 weeks of treatment

  4. Change from baseline in the 7-item Asthma Control Questionnaire (ACQ-7) at Week 12, Week 26 and Week 52 during study visits (using centralized spirometry)

    The 7-item Asthma Control Questionnaire (ACQ-7) score ranges from 0 to 6, with higher scores indicating worse asthma control.

    Time frame: Baseline (pre-dose on Week 0) and Week 12, Week 26, Week 52

  5. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) at Week 12, Week 26 and Week 52 during study visits

    The Asthma Quality of Life Questionnaire (AQLQ) score ranges from 1 to 7, with higher scores indicating better asthma-related quality of life.

    Time frame: Baseline (pre-dose on Week 0) and Week 12, Week 26, Week 52

  6. Change from baseline in pre-dose FEV1 at all clinical visits

    Time frame: Baseline (pre-dose on Week 0) and applicable clinical visits

  7. Change from baseline in 2h post-dose FEV1 at all clinical visits

    Time frame: Baseline (pre-dose on Week 0) and all applicable clinical visits

  8. Proportion of subjects classified as responders in terms of pre-dose FEV1 at Week 26 and Week 52 (i.e., subjects with change from baseline in pre-dose FEV1 ≥100 mL)

    Time frame: Baseline (pre-dose on Week 0) and Week 26, Week 52

  9. Change from baseline in 48h post-dose morning FEV1 after the last intake of study treatment at Week 52

    Time frame: Week 52

  10. Change from baseline in weekly 5-item Asthma Control Questionnaire (ACQ-5) over the 52 weeks of treatment (performed at home by the subject)

    The 5-item Asthma Control Questionnaire (ACQ-5) score ranges from 0 to 6, with higher scores indicating worse asthma control.

    Time frame: Baseline (pre-dose on Week 0) and over the 52 weeks of treatment

  11. Change from baseline in home spirometry parameters (e.g. FEV1, Forced Vital Capacity) over the 52 weeks of treatment (performed at home by the subject)

    Time frame: Baseline (pre-dose on Week 0) and Over the 52 weeks of treatment

07

Study locations

25 sites
  • Institute for Respiratory Diseases Medaimun GmbH
    Frankfurt, Germany
    • Stefan Zielen · Contact
  • Georg-August-Universität Göttingen
    Göttingen, Germany
    • Christiane Lex · Contact
  • Universitätsklinikum Jena
    Jena, Germany
    • Michael Lorenz · Contact
  • Centre for Congenital Heart Defects Stuttgart, Paediatric Intensive Care, Pulmonology and Allergology
    Stuttgart, Germany
    • Marcus Rose · Contact
  • ASST Spedali Civili Brescia
    Brescia, Italy
    • Laura Pini · Contact
  • "A. Perrino" Hospital
    Brindisi, Italy
    • Aniello Meoli · Contact
  • Istituto Giannina Gaslini Pediatric Allergic Center,
    Genoa, Italy
    • Maria Angela Tosca · Contact
  • University of Messina G. Martino Hospital, Allergy and Clinical Immunology Unit
    Messina, Italy
    • Luisa Riccardi · Contact
  • Buzzi Children Hospital
    Milan, Italy
    • Michele Ghezzi · Contact
  • Federico II University, Department of Translational Medical Sciences, Section of Pediatrics
    Naples, Italy
    • Melissa Borrelli · Contact
  • IPAS (Respiratory Diseases of Pediatric Interest) University of Campania 'Luigi Vanvitelli',
    Naples, Italy
    • Michele Miraglia del Giudice · Contact
  • University Hospital of Parma
    Parma, Italy
    • Susanna Maria Roberta Esposito · Contact
  • University Hospital of Pisa, Pediatrics Unit
    Pisa, Italy
    • Maria Elisa di Cicco · Contact
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Woman and Child Health and Public Health
    Roma, Italy
    • Roberta Onesimo · Contact
  • Bambino Gesù Pediatric Hospital IRCCS, Allergy Division
    Rome, Italy
    • Alessandro Fiocchi · Contact
  • IRCCS Humanitas Research Hospital
    Rozzano, Italy
    • Enrico Heffler · Contact
  • Hospital Universitario Germans Trias
    Badalona, Spain
    • Albert Roger Reig · Contact
  • Hospital Sant Joan de Deu
    Barcelona, Spain
    • Jaime Lozano Blasco · Contact
  • Vall d'Hebron University Hospital
    Barcelona, Spain
    • Teresa Garriga-Baraut · Contact
  • Hospital General Universitario Santa Lucia
    Cartagena, Spain
    • Jose Valverde Molina · Contact
  • Hospital Universitario De Jerez Servicio de Pediatría
    Jerez de la Frontera, Spain
    • David Gomez Pastrana · Contact
  • Hospital Universitario Infanta Leonor
    Madrid, Spain
    • Maria Vazquez de la Torre Gaspar · Contact
  • Hospital Universitario Severo Ochoa
    Madrid, Spain
    • Sergio Quevedo Teruel · Contact
  • Hospital Clínico Universitario de Santiago de Compostela
    Santiago de Compostela, Spain
    • Carlos Garcia Magan · Contact
  • IMED Valencia
    Valencia, Spain
    • Noelia Colomer Hernadez · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2030, 43 months later.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 43 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Oct 5, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Jun 26, 2030
CompletionEst.
Jun 26, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858123
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Jun 26, 2030 (estimated)
Completion
Jun 26, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Chiesi Clinical Trial Info
Contact
clinicaltrials_info@chiesi.com
+39 0521 2791
Stefan Zielen, MD
principal investigator · Institut für Atemwegserkrankungen Medaimun GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion